To enhance the secondary anti-tumor specificity, the expression of IL-24 is driven by the human telomerase reverse transcriptase (hTERT) promoter, which is highly active in over 85% of human cancer cells but inactive in most somatic cells. This evidence concerns the gene IL24 and cancer.